Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat
Executive Summary
Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.
You may also be interested in...
Gilead’s Phase III Trial Halt Raises Questions About Magrolimab’s Value
While the myelodysplastic syndrome trial news seems unlikely to read through to other programs, MDS may have been the drug’s biggest market.
China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.
Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.